WBA stock $11.98 NASDAQ 09 Mar 2026: Heavy volume suggests intraday momentum

WBA stock is trading at $11.98 on the NASDAQ in intraday action on 09 Mar 2026, with volume surging to 452,081,061.00 shares versus an average of 16,940,296.00. The price is up 0.06 or 0.50%, while the 52-week range sits between $8.08 and $13.25. Traders have pushed Walgreens Boots Alliance, Inc. (WBA) into the most-active list for the session in the United States, driven by heavy flow and a tight intraday range. Below we break down the technical drivers, fundamental picture, Meyka AI grade, and a forecast comparison that frames the short-term trading case.

WBA stock intraday snapshot and listing details

Walgreens Boots Alliance, Inc. (WBA) trades on the NASDAQ in USD at $11.98 with a market cap of $10,369,421,068.00. Day high and low are both $11.98 on this print, reflecting a tight intraday price. Volume is 452,081,061.00 versus avg volume 16,940,296.00, giving a relative volume of 26.69, which explains its most-active status for the session.

WBA analysis: fundamentals and valuation

Walgreens shows weak earnings metrics: EPS -7.29 and PE -1.64, while price-to-sales is 0.07 and price-to-book is 1.44. The company posts revenue per share 178.73 but negative net margins at -4.07%, and a high debt-to-equity of 4.04, signaling financial strain. We note a low current ratio of 0.60, underscoring liquidity pressure for a retail pharmacy network operating in the Healthcare sector in the United States.

Meyka AI rates WBA with a score out of 100 and technical grade

Meyka AI rates WBA with a score out of 100: 62.52 | Grade B | Suggestion: HOLD. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

WBA forecast and price target scenarios

Meyka AI’s forecast model projects $4.08 versus the current $11.98, implying downside of -65.94%. The broker snapshot shows 1 Hold and 1 Sell, with no consensus price target. Scenario framing: a bear price near the year low $8.08, base at $11.98, and bull toward the year high $13.25. Traders should treat model outputs as projections, not guarantees.

WBA stock technicals and trading flow

Momentum indicators are extreme: RSI 100.00 and ADX 50.00 point to a strong intraday trend. Volatility is modest with ATR 0.16 while Keltner channels centre at 11.93. On-balance volume is 452,081,061.00, matching the session surge. Price movement is small (+0.50%) despite flow, implying activity is driven more by volume spikes than directional conviction.

WBA risks and opportunities for investors

Key risks include high leverage (debt/equity 4.04), negative interest coverage -6.13, and persistent negative EPS. Opportunities stem from steady retail pharmacy cash flow, a large store footprint, and cost moves that can improve margins. The company reports earnings on 2025-06-25, which could reset expectations. Sector context: Healthcare and Medical-Pharmaceutical peer moves will influence WBA stock trading.

Final Thoughts

WBA stock is a clear intraday most-active name on 09 Mar 2026 because volume has spiked to 452,081,061.00 shares while price sits at $11.98 on the NASDAQ in the United States. Fundamentals remain challenged: EPS -7.29, PE -1.64, and a heavy debt load that elevates risk for longer-term holders. Meyka AI rates WBA 62.52/100 (B, HOLD) and flags mixed signals from cash flow versus leverage. Our forecast model projects $4.08, implying -65.94% from today’s price; this is a model-based projection and not a guarantee. For active traders, the stock offers high liquidity and momentum setups but requires strict risk controls because volatility and fundamental stress coexist. For longer-term investors, watch upcoming earnings on 2025-06-25 and debt-reduction progress before adding exposure. For more live context and continuous updates visit the Meyka WBA stock page: Meyka WBA page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.